Pharmaceuticals

DRAXIMAGE(R)'s generic Sestamibi Approved for launch in USA

Published in Medical Letter on the CDC and FDA, May 24th, 2009

Jubilant Organosys Ltd, headquartered in India, announced that its subsidiary in the United States, DRAXIMAGE LLC has received US Food and Drug Administration (FDA) approval for the Company's Abbreviated New Drug Application (ANDA) for DRAXIMAGE(R)'s generic Sestamibi. The product is found to be bioequivalent and therapeutically equivalent to reference listed drug Cardiolite(R).

DRAXIMAGE(R) Sestamibi, is a generic kit used in the preparation of Technetium (Tc-99m) Sestamibi injection - a diagnostic cardiac imaging agent used in Myocardial Perfusion Imaging (MPI), to evaluate the flow of blood to the heart. The MPI market size is currently estimated at USD 400...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2009-05-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry